Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Liquidia Corporation is a biopharmaceutical company specializing in developing, manufacturing, and commercializing innovative therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Utilizing its proprietary PRINT particle engineering technology, the company creates targeted inhaled and injectable drug formulations, focusing on improving safety, efficacy, and patient convenience through novel delivery systems and strategic partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.